Our resource hub to discover reports, policy papers and other forms of informative content
Canadians wait two years for access to new medicines through our public drug plans. That’s a full year longer than patients in most other peer countries. Two years can feel…
…plans. A growing number of European regulatory authorities have been using novel managed entry agreements (MEA) and innovative access agreements (IAA) to accelerate approval times and improve availability to patients….